A Phase 2 interventional study of Obinutuzumab and Corticosteroids in Lymphocytic Leukemia, Chronic, sponsored by Genentech, Inc.. Completed at 31 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-17.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell — 16 open to participants now, 28 under way, 6 of them phase 3. obinutuzumab · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 24th largest by enrollment, is the only one that started in 2011, is one of 30 in phase 2, and was the 2nd registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →16 of the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
BeOne Medicines · Sites in United States, Argentina, Australia and 18 more countries
Ages 18+
PETHEMA Foundation · Sites in Spain
Ages 18+
AbbVie · Sites in United States, Australia, France and 6 more countries
Ages 18+
By country, each count listing its studies:
obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 13
First in 2009; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 72 across the 53 interventional studies. Of the 22 that completed or were terminated, 14 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 53 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 26th largest by enrollment of the 36 interventional ones that give a count, is one of 8 that started in 2011, is one of 13 in phase 2, and was the 23rd registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
12 of the studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT04895436AbbVieStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | 2026-11 |
| NCT05943496OHSU Knight Cancer InstituteTafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | 2027-01-01 |
| NCT04722172Memorial Sloan Kettering Cancer CenterA Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | 2027-02 |
Add all 12 to your calendar (.ics) → With an account.
Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This open-label, multicenter, randomized study compared the efficacy, safety and pharmacokinetics of obinutuzumab (RO5072759; GA101) 1000 mg versus 2000 mg in participants with previously untreated CLL. Participants were randomized to receive a maximum of 8 cycles (28-day cycle) of obinutuzumab (1000 mg intravenous [IV] infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of each subsequent cycle up to 8 cycles or maximum of 8 cycles of obinutuzumab (2000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of each subsequent cycle up to 8 cycles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a 1000 mg intravenous (IV) infusion, on days 1 (split dose 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1 and day 1 of cycles 2 - 8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
Drug: Obinutuzumab · Drug: Corticosteroids
Participants received a 2000 mg IV infusion, on days 1 (split dose 100 mg Day 1, 900 mg Day 2 and 1000 mg Day 3), 8 and 15 of cycle 1 and day 1 of cycles 2 -8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
Drug: Obinutuzumab · Drug: Corticosteroids
Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.
Also known as: RO5072759; GA101
Participants were administered corticosteroids IV prior to the initial dose.
Objective Response Rate (ORR)
ORR was defined as the percentage of participants with complete response (CR), CR with incomplete marrow recovery (CRi) or partial response (PR) as assessed by the investigator according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines two months after last treatment. CR required: blood lymphocytes \< 4 x 10\^9/Liter (L), absence of lymphadenopathy (≤ 1.5 centimeter (cm) in long axis by Computed Tomography), no hepatomegaly or splenomegaly, absence of disease, Neutrophils \> 1.5 x 10\^9/L, Platelets \> 100 x 10\^9/L, Hemoglobin \>11 g/dL, bone marrow normal and lymphoid nodules absent. CRi was CR with incomplete marrow recovery. PR required: 50% decrease in peripheral blood lymphocyte count, 50% reduction in lymphadenopathy, 50% reduction of liver and/or spleen enlargement if enlarged at baseline, Neutrophils \> 1.5 x 10\^9/L or \> 50% of pretreatment value, Platelets \> 100 x 10\^9/L or 50% of pretreatment value and Hemoglobin \> 11 g/dL or \> 50% of pretreatment value.
Time frame: Week 32
Progression-free Survival (PFS)
PFS was defined as the time from the randomization to the first occurrence of progression or death, whichever occurred first.
Time frame: Up to 4 years, 5 months
Duration of Response
Time frame: Up to 4 years, 5 months
Number of Participants Surviving at End-of-Study
Time frame: Up to 4 years, 5 months
Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution. A SAE was any AE that was one of the following: fatal, life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product or considered a significant medical event by the investigator. Additional information about AEs can be found in the Adverse Event Section.
Time frame: Up to 4 years, 5 months
Percentage of Participants With Adverse Events of Interest
Adverse Events of interest for this study were: serious infusion related reactions during or within 24 hours of infusion, serious neutropenia, serious infection, tumor lysis syndrome and Hepatitis B reactivation.
Time frame: Up to 4 years, 5 months
Percentage of Participants With Adverse Events Leading to Study Discontinuation
An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution.
Time frame: Up to 4 years, 5 months
PK Parameter: Maximum Serum Concentration (Cmax)
Blood was collected for Pharmacokinetic (PK) Parameter Cmax after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in micrograms per milliliter (μg/mL).
Time frame: Day 148 (at end of infusion)
PK Parameter: Area Under the Serum Concentration-Time Curve Between Dosing Interval Tau (AUCt )
Blood was collected for PK Parameters before and after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in day times micrograms per milliliter (day\*μg/mL).
Time frame: Day 148 (pre-infusion, at end of infusion, 5, 8 and 12 days after start of infusion)
PK Parameter: Clearance at Steady State (CLss)
Blood was collected for PK Parameters before and after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). CLss is reported in milliliters per day (mL/day).
Time frame: Day 148 (pre-infusion, at end of infusion, 5, 8 and 12 days after start of infusion)
PK Parameter: Volume of Distribution at Steady State (Vss)
Blood was collected for PK Parameters before and after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Vss is reported in liters.
Time frame: Day 148 (pre-infusion, at end of infusion, 5, 8 and 12 days after start of infusion)
PK Parameter: Terminal Half-Life (t1/2)
Blood was collected for PK Parameters before and after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). T1/2 was reported in Days.
Time frame: Day 148 (pre-infusion, at end of infusion, 5, 8 and 12 days after start of infusion)
PK: Serum Concentrations of Obinutuzumab (Follow-Up Visits)
Blood serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in micrograms per milliliter (μg/mL).
Time frame: Months 3, 6, 9, and 12
Pharmacodynamics: Number of Participants With Peripheral Blood B-cell Depletion
Blood was sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry. B-cell depletion was defined as a CD19 result \< 0.07 × 10\^9/L after at least one dose of study drug has been administered.
Time frame: Up to 4 years, 5 months
Pharmacodynamics: Number of Participants With Peripheral Blood B-cell Recovery
Blood was sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry. B-cell recovery was defined as a CD19 result ≥ 0.07 × 10\^9/L, where CD19 was previously depleted. B-cell recovery was only considered possible following the last dose of study treatment. The number of participants with B-cell recovery from End of Treatment to 6 months of Follow-up is reported in two categories: Recovery with Progressive Disease (PD) \[PD before B-cell recovery or PD within 45 days after recovery\] or Recovery without PD. PD required one of the following: 50% increase in the absolute number of circulating lymphocytes, Appearance of new palpable lymph nodes, 50% increase in the longest diameter of any previous site of lymphadenopathy, 50% increase in the enlargement of the liver and/or spleen or Transformation to a more aggressive histology.
Time frame: Up to 4 years, 5 months
| Milestone | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| Started | 41 | 39 |
| Received study drug | 40 | 38 |
| Completed | 34 | 32 |
| Not completed | 7 | 7 |
| Withdrew: Death | 5 | 1 |
| Withdrew: Lost to follow-up | 1 | 4 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Randomized but not treated | 1 | 1 |
ORR was defined as the percentage of participants with complete response (CR), CR with incomplete marrow recovery (CRi) or partial response (PR) as assessed by the investigator according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines two months after last treatment. CR required: blood lymphocytes \< 4 x 10\^9/Liter (L), absence of lymphadenopathy (≤ 1.5 centimeter (cm) in long axis by Computed Tomography), no hepatomegaly or splenomegaly, absence of disease, Neutrophils \> 1.5 x 10\^9/L, Platelets \> 100 x 10\^9/L, Hemoglobin \>11 g/dL, bone marrow normal and lymphoid nodules absent. CRi was CR with incomplete marrow recovery. PR required: 50% decrease in peripheral blood lymphocyte count, 50% reduction in lymphadenopathy, 50% reduction of liver and/or spleen enlargement if enlarged at baseline, Neutrophils \> 1.5 x 10\^9/L or \> 50% of pretreatment value, Platelets \> 100 x 10\^9/L or 50% of pretreatment value and Hemoglobin \> 11 g/dL or \> 50% of pretreatment value.
| Percentage of participants | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| Objective Response Rate (ORR) | 48.8 | 66.7 |
PFS was defined as the time from the randomization to the first occurrence of progression or death, whichever occurred first.
| Months | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| Progression-free Survival (PFS) | 25.2 (15.9 to 30.4) | 26.0 (20.2 to 34.2) |
Results for this outcome have not been posted.
| Participants | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| Number of Participants Surviving at End-of-Study | 35 | 37 |
An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution. A SAE was any AE that was one of the following: fatal, life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product or considered a significant medical event by the investigator. Additional information about AEs can be found in the Adverse Event Section.
| Percentage of participants | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| Adverse Events | 100.0 | 100.0 |
| Serious Adverse Events | 20.0 | 21.1 |
Adverse Events of interest for this study were: serious infusion related reactions during or within 24 hours of infusion, serious neutropenia, serious infection, tumor lysis syndrome and Hepatitis B reactivation.
| Percentage of participants | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| Serious Infusion-Related Reactions (IRR) | 7.5 | 5.3 |
| Serious Neutropenia | 5.0 | 5.3 |
| Serious Infection | 5.0 | 5.3 |
| Tumor Lysis Syndrome | 0.0 | 2.6 |
| Hepatitis B Reactivation | 0.0 | 0.0 |
An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution.
| Percentage of participants | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| Percentage of Participants With Adverse Events Leading to Study Discontinuation | 0 | 0 |
Blood was collected for Pharmacokinetic (PK) Parameter Cmax after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in micrograms per milliliter (μg/mL).
| μg/mL | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| PK Parameter: Maximum Serum Concentration (Cmax) | 600 ± 45.6 | 1190 ± 34.9 |
Blood was collected for PK Parameters before and after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in day times micrograms per milliliter (day\*μg/mL).
| day*μg/mL | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| PK Parameter: Area Under the Serum Concentration-Time Curve Between Dosing Interval Tau (AUCt ) | 8230 ± 58.3 | 16500 ± 50.3 |
Blood was collected for PK Parameters before and after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). CLss is reported in milliliters per day (mL/day).
| mL/day | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| PK Parameter: Clearance at Steady State (CLss) | 121 ± 58.3 | 122 ± 50.3 |
Blood was collected for PK Parameters before and after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Vss is reported in liters.
| Liters | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| PK Parameter: Volume of Distribution at Steady State (Vss) | 7.08 ± 73.2 | 6.68 ± 74.7 |
Blood was collected for PK Parameters before and after dose administration on Day 1 of Cycle 8. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). T1/2 was reported in Days.
| Days | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| PK Parameter: Terminal Half-Life (t1/2) | 30.6 ± 87.1 | 26.3 ± 80.1 |
Blood serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in micrograms per milliliter (μg/mL).
| μg/mL | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| Month 3 (n=14, 10) | 41.2 ± 63.3 | 98.9 ± 88.9 |
| Month 6 (n=19, 15) | 15 ± 21.4 | 12.6 ± 17.7 |
| Month 9 (n=24, 23) | 2.63 ± 4.4 | 4.09 ± 9.42 |
| Month 12 (n=16, 18) | 0.633 ± 1.11 | 0.857 ± 1.74 |
Blood was sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry. B-cell depletion was defined as a CD19 result \< 0.07 × 10\^9/L after at least one dose of study drug has been administered.
| Participants | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| At Last Antibody Administration (n=40, 38) | 31 | 31 |
| Up to 6 Months of Follow-Up (FU) (n=30, 31) | 28 | 28 |
| Within 6-12 Months of Follow-up (n=24, 24) | 16 | 17 |
| Within 12-18 Months of Follow-up (n=17, 17) | 11 | 9 |
| Within 18-24 Months of Follow-up (n=10, 9) | 5 | 8 |
| Within 24-30 Months of Follow-up (n=4, 6) | 2 | 5 |
| Within 30-36 Months of Follow-up (n=1, 3) | 1 | 3 |
| Within 36-42 Months of Follow-up (n=0, 0) | 0 | 0 |
| After 42 Months of Follow-up (n=0, 0) | 0 | 0 |
Blood was sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry. B-cell recovery was defined as a CD19 result ≥ 0.07 × 10\^9/L, where CD19 was previously depleted. B-cell recovery was only considered possible following the last dose of study treatment. The number of participants with B-cell recovery from End of Treatment to 6 months of Follow-up is reported in two categories: Recovery with Progressive Disease (PD) \[PD before B-cell recovery or PD within 45 days after recovery\] or Recovery without PD. PD required one of the following: 50% increase in the absolute number of circulating lymphocytes, Appearance of new palpable lymph nodes, 50% increase in the longest diameter of any previous site of lymphadenopathy, 50% increase in the enlargement of the liver and/or spleen or Transformation to a more aggressive histology.
| Participants | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| Up to 6 Months FU: Recovery with PD (n=30, 31) | 0 | 0 |
| Up to 6 Months FU: Recovery without PD (n=30, 31) | 2 | 3 |
| 6-12 Months FU: Recovery with PD (n=24, 24) | 1 | 0 |
| 6-12 Months FU: Recovery without PD (n=24, 24) | 7 | 7 |
| 12-18 Months FU: Recovery with PD (n=17, 17) | 0 | 0 |
| 12-18 Months FU: Recovery without PD (n=17, 17) | 6 | 8 |
| 18-24 Months FU: Recovery with PD (n=10, 9) | 0 | 0 |
| 18-24 Months FU: Recovery without PD (n=10, 9) | 5 | 1 |
| 24-30 Months FU: Recovery with PD (n=4, 6) | 0 | 0 |
| 24-30 Months FU: Recovery without PD (n=4, 6) | 2 | 1 |
| 30-36 Months FU: Recovery with PD (n=1, 3) | 0 | 0 |
| 30-36 Months FU: Recovery without PD (n=1, 3) | 0 | 0 |
| 36-42 Months FU: Recovery with PD (n=0, 0) | 0 | 0 |
| 36-42 Months FU: Recovery without PD (n=0, 0) | 0 | 0 |
| After 42 Months FU: Recovery with PD (n=0, 0) | 0 | 0 |
| After 42 Months FU: Recovery without PD (n=0, 0) | 0 | 0 |
Collected over Up to 4 years, 5 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Obinutuzumab 1000 mg | — | 8/40 (20%) | 40/40 (100%) |
| Obinutuzumab 2000 mg | — | 8/38 (21.1%) | 38/38 (100%) |
| Event | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 2/40 | 1/38 |
| Infusion related reactionInjury, poisoning and procedural complications | 2/40 | 0/38 |
| NeutropeniaBlood and lymphatic system disorders | 0/40 | 1/38 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/40 | 1/38 |
| SepsisInfections and infestations | 0/40 | 1/38 |
| UrosepsisInfections and infestations | 0/40 | 1/38 |
| Acute coronary syndromeCardiac disorders | 0/40 | 1/38 |
| Sinus bradycardiaCardiac disorders | 0/40 | 1/38 |
| FallInjury, poisoning and procedural complications | 0/40 | 1/38 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/40 | 1/38 |
| Event | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg |
|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 30/40 | 24/38 |
| PyrexiaGeneral disorders | 16/40 | 18/38 |
| FatigueGeneral disorders | 16/40 | 12/38 |
| NauseaGastrointestinal disorders | 15/40 | 10/38 |
| NeutropeniaBlood and lymphatic system disorders | 14/40 | 12/38 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/40 | 11/38 |
| VomitingGastrointestinal disorders | 11/40 | 5/38 |
| HeadacheNervous system disorders | 11/40 | 4/38 |
| DizzinessNervous system disorders | 10/40 | 7/38 |
| FlushingVascular disorders | 8/40 | 9/38 |
| Age, Continuous(years) | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg | Total |
|---|---|---|---|
| Mean | 67.0 ± 10.0 | 64.3 ± 12.4 | 65.7 ± 11.2 |
| Sex: Female, Male(Participants) | Obinutuzumab 1000 mg | Obinutuzumab 2000 mg | Total |
|---|---|---|---|
| Female | 16 | 13 | 29 |
| Male | 25 | 26 | 51 |
Ran from Oct 2011 to primary completion in Mar 2013, 17 months.
Results were first posted in Apr 2014, 1 year after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 17 months is below that.
Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab
Leukemia, Lymphocytic, Chronic, B-Cell →